Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves
- 1 June 2007
- journal article
- Published by Taylor & Francis Ltd in Expert Opinion on Drug Discovery
- Vol. 2 (6), 849-860
- https://doi.org/10.1517/17460441.2.6.849
Abstract
The selection of appropriate doses and dosing regimens is extremely important in antimicrobial therapy in order to increase the chances of clinical success and decrease the likelihood of toxic side effects and the development of resistance. Therefore, empirical treatment of bacterial infections is not reliable enough and more rational approaches are needed. Pharmacokinetic/pharmacodynamic (PK/PD) modeling provides a powerful tool to systematically link PK and PD properties in order to predict antimicrobial efficacy. However, commonly used minimum inhibitory concentration (MIC) based PK/PD indices, although easy to obtain, have a number of limitations. Thus, more reliable PK/PD indices need to be developed. The following article provides an overview of the present PK/PD approaches used in anti-infective therapy and discusses their role in improving drug therapy.Keywords
This publication has 90 references indexed in Scilit:
- Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve ExperimentsAntimicrobial Agents and Chemotherapy, 2007
- Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelDiagnostic Microbiology and Infectious Disease, 2006
- Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomiesDiagnostic Microbiology and Infectious Disease, 2006
- Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill KineticsClinical Pharmacokinetics, 2005
- Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious DiseasesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- In Vitro Bactericidal Activities of ABT-773 against ermB Strains of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2003
- The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibioticsResearch in Veterinary Science, 2002
- Clinical Use of CeftriaxoneClinical Pharmacokinetics, 2001
- Achieving an Optimal Outcome in the Treatment of InfectionsClinical Pharmacokinetics, 1999
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995